Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis

BMJ (Online)

Volumn 341, Issue 7775, 2010, Pages 711-

  Wandel, Simon ^a,b   Jüni, Peter ^a,b   Tendal, Britta ^c   Nüesch, Eveline ^a,b   Villiger, Peter M ^b   Welton, Nicky J ^d   Reichenbach, Stephan ^a,b   Trelle, Sven ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Nordic Cochrane Centre   (Denmark)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN; GLUCOSAMINE; PLACEBO;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; HIP OSTEOARTHRITIS; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS; CHONDROITIN; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77957342022     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4675     Document Type: Article

References (58)

1. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal antiinflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
2. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al. Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med 2000;133:726-37.
3. Annual nutrition industry overview. Nutrition Business J 2005;X:6-7.
4. Heller L. US glucosamine grows slow, lags global sales. 2009. www. nutraingredients-usa.com/Consumer-Trends/US-glucosaminegrows-slow-lags-global- sales.
5. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995;45:918-25.
6. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartil 1998;6:14-21.
7. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil 2007;15:764-72. (Pubitemid 46888164)
8. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. JAMA 2000;283:1469-75.
9. Jüni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol 2006;20:721-40.
10. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-90.
11. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007;56:2267-77.
12. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al. The effects of the exclusion of patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ 2009;339:b3244.
13. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
14. Lumley T. Networkmeta-analysis for indirect treatment comparisons. Stat Med 2002;21:2313-24.
15. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48. (Pubitemid 47393576)
16. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
17. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91. (Pubitemid 24340510)
18. Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
19. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6. (Pubitemid 32682008)
20. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685-99.
21. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
22. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166:1269-75. (Pubitemid 43967578)
23. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Lawrence Erlbaum, 1988.
24. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992;45:769-73.
25. Eberle E, Ottillinger B. Clinically relevant change and clinically relevant difference in knee osteoarthritis. Osteoarthr Cartil 1999;7:502-3. (Pubitemid 29468746)
26. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384-91.
27. Angst F, Aeschlimann A, Michel BA, Stucki G. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol 2002;29:131-8.
28. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8:283-91.
29. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:a1331.
30. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
31. Lu G, Ades AE. Assessing evidence inconsistency inmixed treatment comparisons. J Am Stat Assoc 2006;101:447-59. (Pubitemid 43972289)
32. Brooks S, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55. (Pubitemid 128635035)
33. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthr Cartil 1994;2:51-9.
34. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6. (Pubitemid 32120855)
35. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23. (Pubitemid 35168220)
36. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004;117:643-9. (Pubitemid 40288170)
37. Michel BA, Stucki G, Frey D, De Vathaire F, Vignon E, Bruehlmann P, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86. (Pubitemid 40365099)
38. Mazières B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007;66:639-45. (Pubitemid 46707133)
39. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007;56:555-67. (Pubitemid 46271981)
40. Helg AG. How solid are the results of the meta-analysis by Reichenbach et al and its conclusions? Ann Intern Med 2009. www.annals.org/content/146/8/580. abstract/reply#annintmed-el-44993.
41. Rozendaal RM, Koes BW, van Osch GJ, Uitterlinden EJ, Garling EH, Willemsen SP, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008;148:268-77.
42. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO 3rd, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008;58:3183-91.
43. Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. Longterm effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33.
44. Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003;7:1-76.
45. Egger M, Smith GD. Principles of and procedures for systematic reviews. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care:meta-analyis in context. BMJ Publishing, 2001:23-42.
46. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: metaepidemiological study. BMJ 2008;336:601-5. (Pubitemid 351439518)
47. Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ. Combining scores from different patient reported outcome measures in meta-analyses: when is it justified? Health Qual Life Outcomes 2006;4:94.
48. Gentelle-Bonnassies S, Le Claire P, Mezieres M, Ayral X, Dougados M. Comparison of the responsiveness of symptomatic outcome measures in knee osteoarthritis. Arthritis Care Res 2000;13:280-5.
49. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.
50. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic reviewof randomized controlled trials. Ann Pharmacother 2005;39:1080-7.
51. Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008;9:165.
52. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a metaanalysis. Rheumatol Int 2010;30:357-63.
53. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007;56:2105-10.
54. Fortin PR, Stucki G, Katz JN. Measuring relevant change: an emerging challenge in rheumatologic clinical trials. Arthritis Rheum 1995;38:1027-30.
55. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
56. Fransen M, Day R, Bridges-Webb C, Edmonds J, Norton R, Woodward M, et al. The long-term evaluation of glucosamine sulphate study (LEGS). 2009. http://clinicaltrials.gov/ct2/show/NCT00513422.
57. Felson DT. Chondroitin for pain in osteoarthritis. Ann Intern Med 2007;146:611-2.
58. Krogsboll LT, Hrobjartsson A, Gotzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 2009;9:1.